Cause of lower corona infection in Asia:
SARS-CoV-2 was first reported from China. Within three months, it evolved to 10 additional subtypes. Two evolved subtypes (A2 and A2a) carry a non-synonymous Spike protein mutation (D614G).
A new study:
A phylodynamic analysis of over 70,000 SARS-CoV-2 coronaviruses worldwide, sequenced until July2020, and found that the mutant sub-type (614G) out competed the pre-existing type (614D), significantly faster in Europe and North-America than in East Asia. A study has concluded that:
Britain’s Pfizer Vaccine:
Britain’s Medicines and Healthcare Products Regulatory Agency (MHRA) became the first nation in the world to approve the corona aka Covid-19 vaccine last week. The vaccine is developed by Germany’s BioNTech and Pfizer. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) are still assessing the data for the trial.
The Medicines and Healthcare Products Regulatory Agency (MHRA) said there had been two reports of anaphylaxis and one report of a possible allergic reaction since the rollout began. MHRA Chief Executive June Raine has issued following statement:
“Any person with a history of anaphylaxis to a vaccine, medicine or food should not receive the Pfizer BioNTech vaccine ……….. Most people will not get anaphylaxis and the benefits in protecting people against COVID-19 outweigh the risks… You can be completely confident that this vaccine has met the MHRA’s robust standards of safety, quality and effectiveness.”
What is anaphylaxis shock?
The Serum Institute of India (SII) is being sued.
A volunteer engaged for the trial of Corona vaccine has sued SII seeking damages of Rs 5 crore from SII. Accordiing to the legal notice the 40-year-old male volunteer developed serious neurological impairment after the under-trial vaccine was administered to him.
Yesterday Serum Institute (SII) counter-sued the aforesaid volunteer (who developed an adverse event following the administration of the Oxford vaccine in a late-stage trial in India) SII has termed the volunteer’s legal notice “malicious and misconceived” and it sought “damages in excess of Rs 100 crore” for maligning the reputation of the company.
SII had not made any public disclosure:
Cold Chain is not a big problem in India:
Rumours are spread by the media in India and abroad that India is a big and poor country. How will it manage Cold Chain required for preserving the Vaccine? Is this misinformation aimed at creating panic? There are no easy answers. But India does not have this problem.
Requirement of Cold Chain:
It is true that all the vaccines Pfizer-BioNTech, Sputnik-V and Moderna require a temperature of anywhere between minus 18 degrees to minus 90 degrees Celsius, except for the vaccine being developed by Oxford University-AstraZeneca, which can be stored in normal household refrigerators with a temperature range of 2 degrees to 8 degrees Celsius.
As usual the media has being crying hoarse that poor India does not have capability of cold chain required for transportation of vaccine.
Cold Chain capability of India:
Shashi Tharoor is member of parliament from Thiruvantpuram, the capital of State of Kerala and he is very dissatisfied with the performance of India in Corona Pandemic. His party i.e. rules Punjab where the death toll is highest. The case fatality rate, as it is known, in Punjab is over 3% approx. as against national average of 1.5% approx. The learned MP had granted his constituency Oxyzen concentrators, though the same have not been delivered till recently. See this tweet:
Precarious Finances of Kerala
Kerala is facing a record fiscal deficit following the economic crisis triggered by the Covid pandemic. As per the evaluation made for the first quarter of the current financial year, the state’s fiscal deficit stood at 112.9 per cent which comes to the tune of 10,578 crores. It also pointed out that if financial assistance from the Centre including GST compensation if not received immediately, the state could plunge into a deep financial crisis in the coming days.
Impropriety in Governance: